Inogen Inc Stock Price, News & Analysis

Inogen (Nasdaq: INGN) announced the U.S. launch of Aurora CPAP masks for obstructive sleep apnea on January 7, 2026, expanding its respiratory care portfolio into the sleep-therapy market.

Key facts: FDA 510(k) cleared masks offered through certified partners; portfolio includes F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows; product claims universal CPAP compatibility, quiet venting, and simple maintenance. A 30-day AMG trial of 140 patients reported a majority were highly satisfied.

Inogen (NASDAQ: INGN) reported Q3 2025 results on November 5, 2025 with $92.4 million revenue, up 4.0% year-over-year, marking the seventh consecutive quarter of mid-single-digit growth. GAAP net loss was $5.3 million (including $1.8 million of one-time legal and settlement expenses) while adjusted net loss narrowed to $0.5 million and adjusted EBITDA was $2.3 million, the third straight quarter of positive adjusted EBITDA.

The company generated $2.2 million of positive operating cash flow and ended the quarter with $124.5 million in cash, equivalents, marketable securities and restricted cash, with no debt outstanding. Inogen reiterated full-year revenue guidance of $354M–$357M and raised full-year adjusted EBITDA guidance to approximately $2 million. The company also initiated a limited U.S. release of the Simeox airway clearance device.

Inogen (Nasdaq: INGN) will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. The company will host a conference call the same day at 5:30 a.m. PT / 8:30 a.m. ET with live audio webcast and an archived recording available on the Inogen Investor Relations website.

A replay will be available approximately three hours after the live webcast and accessible through November 12, 2025 via dial-in using Conference ID 13755676. The webcast archive will remain on the IR site for six months. Inogen notes it uses its investor website to disclose material information and comply with Regulation FD.

Inogen (NASDAQ: INGN), a medical technology company specializing in respiratory products, has appointed Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Rameswamy joins from Alcon, where he served as Vice President and Global Head of Digital Health Platforms.

With over 20 years of medical device industry experience, Rameswamy previously held leadership positions at GE Healthcare, where he advanced device connectivity, remote diagnostics, and care management platforms. His expertise in digital health and connected device innovation aligns with Inogen's strategy to enhance its technology leadership in the respiratory care market.

Inogen (NASDAQ: INGN), a medical technology company specializing in respiratory products, reported its Q2 2025 financial results with revenue of $92.3 million, marking a 4.0% year-over-year increase and the sixth consecutive quarter of mid-single-digit growth.

The company reported a GAAP net loss of $4.2 million and adjusted net loss of $0.7 million, while delivering positive adjusted EBITDA of $2.1 million. Q2 gross margin was 44.8%, down from 48.1% in the prior year. Cash position strengthened to $123.7 million with no debt.

Notable developments include the launch of Voxi™ 5, a new stationary oxygen concentrator, and the Inogen Patient Portal. The company raised its full-year 2025 revenue guidance to $354-357 million, representing approximately 6% growth.

Inogen (NASDAQ: INGN), a medical technology company specializing in innovative respiratory products for homecare, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can access the call via US domestic line (877) 841-3961 or international line (201) 689-8589. A live webcast and replay will be available on Inogen's Investor Relations website for 6 months, with call replay accessible through August 14, 2025.

Inogen (NASDAQ: INGN) has launched Voxi 5, a new stationary oxygen concentrator designed to provide affordable and durable oxygen therapy for long-term care patients. Developed with Yuwell Medical, the device delivers 1-5 L/min of continuous flow oxygen with 87-96% concentration. Key features include quiet operation at 45dBA, compact 16.7-inch height design with lockable casters for mobility, an 8-layer internal gas pathway for medical-grade oxygen, and a 3-year sieve bed warranty for up to 8,000 hours. The Voxi 5 complements Inogen's existing At Home product line, targeting price-sensitive customers and multi-room use cases. This launch expands Inogen's market potential while utilizing existing sales channels, reinforcing their position in the home oxygen therapy market.

Inogen (NASDAQ: INGN) reported its Q1 2025 financial results, showing revenue growth of 5.5% to $82.3 million, driven by increased international and domestic B2B customer demand. The company's gross margin improved slightly to 44.2%. Operating expenses decreased by 13.1% to $44.0 million. While still reporting losses, INGN significantly reduced its GAAP net loss to $6.2 million from $14.6 million year-over-year, and adjusted net loss improved to $2.9 million. The company achieved positive adjusted EBITDA of $0.04 million, compared to negative $7.6 million in the prior year. Inogen maintains a strong balance sheet with $122.5 million in cash and no debt. For full-year 2025, the company expects revenue between $352-355 million, representing 5-6% growth, and aims to approach adjusted EBITDA breakeven.

Inogen (NASDAQ: INGN), a medical technology company specializing in innovative respiratory products for homecare, has scheduled its first quarter 2025 financial results announcement for May 7, 2025, after market close.

The company will host a conference call the same day at 2:00 p.m. PT / 5:00 p.m. ET. Investors can join via phone using the following numbers: US domestic (877) 841-3961 and Non-US (201) 689-8589. A live audio webcast will be available through the News / Events page on Inogen's Investor Relations website, with a 6-month archive period. Call replay access will be available until May 14, 2025, via (877) 660-6853 or (201) 612-7415 with Conference ID: 13752582.